As it gets the OK for a new rapid Covid-19 detecting device, Abbott Labs could be purchased here following our new technical strategy.
While the short-term picture of JNJ suggests more risk is possible, the longer-term patterns are constructive.
Japan is a leader in pharmaceuticals and has three companies working overtime to develop treatments for Covid-19.
I do believe that having no economy is temporary. I also believe that what comes out on the other side will be smaller, far less global.
The drug and vaccine maker possibly could see its shares double according to a key chart.
These pharmaceutical names have what it takes amid the current crisis and for the long run.
A strong S&P for three days makes me leery of what's ahead, but here's an option in JNJ.
The Holy Grail right now are the few companies thriving and that will keep going after this is over, but there are others who will rebound and some who will not.
The healthcare giant's charts still show some signs of weakness but also indicate it could rally and make a base from a higher level.
Traders who are comfortable with risk could consider buying QDEL closer to $85 if available.